Active Filter(s):
Details:
The funding will support company's lead therapeutic approach that inhibits Gasdermin D, which has been recently discovered as a key target at the core of multiple inflammatory cell death pathways.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 27, 2020